PMID- 7544989
OWN - NLM
STAT- MEDLINE
DCOM- 19951010
LR  - 20180222
IS  - 0029-0831 (Print)
IS  - 0029-0831 (Linking)
VI  - 27
IP  - 3
DP  - 1995 May
TI  - [Successful treatment of subacute sclerosing panencephalitis with long-term 
      intrathecal large dose of alpha-interferon--a case report].
PG  - 231-7
AB  - Recent effective treatments for subacute sclerosing panencephalitis (SSPE) are 
      oral inosiplex and intrathecal interferon therapy. The former seems to be 
      effective for life expectancy but not for neurological disability, and the latter 
      is a debating antiviral treatment although favorable reports are increasing. A 12 
      year-10 month-old boy with SSPE was presented as a successful case of prolonged 
      effectiveness in both neurological symptoms and life expectancy. There are no 
      significant side effects by the 200 weeks treatment of intrathecal 
      alpha-interferon of large dose (6 million unit/dose/week) and ordinary dose of 
      inosiplex (100 mg/kg/day). Neurological disability index (Dyken) improved from 
      70% to 10%; speech and higher cerebral functions improved from aphasia and almost 
      vegetative states to verbal communicable level; motor dysfunction from bedridden 
      to wheel chair level; and myoclonic and other seizures were controlled. 
      Laboratory data also improved; periodic synchronized discharge (PSD) and other 
      paroxysmal discharges disappeared and alpha activity that had once disappeared in 
      the background activity of active stages reappeared in the EEGs. Measles 
      antibodies in serum and CSF improved, and oligoclonal bands disappeared. However 
      diffuse brain atrophy remained on neuroimaging. Long-term intrathecal large dose 
      treatment with alpha-interferon is effective and safe. It should be started as 
      soon as the diagnosis is made, and a trial of large-dose and long-term therapy 
      may be worthy even for more advanced cases irrespective of progress of 
      neuroimages.
FAU - Horiguchi, Y
AU  - Horiguchi Y
AD  - Department of Pediatrics, Kitasato University School of Medicine, Sagamihara.
FAU - Ohya, T
AU  - Ohya T
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - No To Hattatsu
JT  - No to hattatsu = Brain and development
JID - 0215224
RN  - 0 (Interferon-alpha)
RN  - W1SO0V223F (Inosine Pranobex)
SB  - IM
MH  - Child
MH  - Combined Modality Therapy
MH  - Humans
MH  - Injections, Spinal
MH  - Inosine Pranobex/therapeutic use
MH  - Interferon-alpha/*administration & dosage
MH  - Male
MH  - Subacute Sclerosing Panencephalitis/*therapy
EDAT- 1995/05/01 00:00
MHDA- 1995/05/01 00:01
CRDT- 1995/05/01 00:00
PHST- 1995/05/01 00:00 [pubmed]
PHST- 1995/05/01 00:01 [medline]
PHST- 1995/05/01 00:00 [entrez]
PST - ppublish
SO  - No To Hattatsu. 1995 May;27(3):231-7.